Clinical observation of autologous peripheral blood stem cell transplantation for treatment of acute lymphocytic leukemia

Objective To evaluate the therapeutic effects of autologous peripheral blood stem cell transplantation (APBSCT) on the treatment of acute lymphocytic leukemia (ALL). Methods Seventeen ALL patients were recruited in this APBSCT study, in which eleven patients were in the first complete remission (CR1) and six in the second complete remission (CR2). Combined chemotherapy regimen(MOEP or CMOP)followed by G CSF was used for PBSC mobilization and collected a median mononuclear cells (MNC) of 4.8×10 8/kg, CD34 + cells 5.7×10 6/kg and CFU GM 4.1×10 5/kg. Conditioning regimens were Cy 120mg/kg plus TBI 7.5 9Gy or IEAC(ID,VP16,Ara C,CTX ). Results All patients were engrafted and hematopoietic reconstitution was rapid: the mean days of ANC recovery were 10 days up to 0.5×10 9/L and PLT 15 days up to 20×10 9/L. After APBSCT, nine patients were event free survival (EFS) and two died in the CR1 patients, those in the CR2 patients, three EFS and three died. Conclusion Our study suggests that APBSCT is a safety and an effective therapeutic option in ALL patients, the optimal time to transplant should be in the CR1 of ALL.